106 Views

Mint Solutions bags Series A funds

Mint Solutions said Tuesday that it has secured 4.425 million euros in Series A financing. The investors included Life Sciences Partners and Seventure Partners. In conjunction with the funding, Anne Portwich of LSP and Eric de La Fortelle of Seventure Partners have been added to Mint Solutions’ board of directors. Mint Solutions is is a developer of MedEye, which helps patients get the right medication at the right time.

Rotation Medical snags $27.2 mln Series B

Rotation Medical, a medical device firm focused on rotator cuff disease, has closed $27.2 million in Series B funding. Life Sciences Partners and New Enterprise Associates led the round with participation from investors that included Pappas Ventures. In conjunction with the funding, Dr. Azzam of LSP and Scott Weiner of Pappas Ventures have been added to Rotation Medical’s board of directors.

Atlas Genetics nabs Series B funds

Atlas Genetics has raised 16.9 million pounds in Series B funding. The investors in this round include Novartis Venture Funds, Consort Medical plc, Life Sciences Partners, BB Biotech Ventures, Johnson & Johnson Development Corp. and YFM Equity Partners. Based in Bath, England, Atlas is a diagnostics company that provides tests for infectious diseases.

Kawola Joins Harvest Automation as CEO

Harvest Automation, a company developing practical robots for the agriculture industry, has appointed John Kawola as CEO. Current CEO Charles Grinnell will assume the role of COO. Backed by Entrée Capital, Founder Collective, Life Sciences Partners, Cultivian Ventures, and Massachusetts Technology Development Corporation, Harvest Automation is headquartered outside of Boston, Mass.

Kiadis Pharma Secures Financing

Kiadis Pharma, a clinical stage biopharmaceutical company developing treatments for blood cancers, has raised 10 million euros ($12.8 million) in an equity financing round. The round was led by Life Sciences Partners and supported by a large investment from DFJ-Esprit. Other investors included Alta Partners, Quest for Growth and NOM.

Prosensa Raises Funding Round

Prosensa, a Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases, has raised €23 million (US$29.8 million) in new equity financing. The financing was led by new investor New Enterprise Associates (NEA) and was supported by existing investors, Abingworth, Life Sciences Partners, Gimv, Idinvest Partners and MedSciences Capital. PRESS RELEASE Prosensa, the Dutch biopharmaceutical […]

Mendor Inks $11.6M in Series B

Helsinki-based healthcare company Mendor has closed on 8.1 million euros ($11.64 million) in Series B financing from Finnish entrepreneur and investor Risto Siilasmaa, Life Sciences Partners, Finnish Industry Investment Ltd., Finnish Mutual Pension Insurance Company Ilmarinen, private Finnish investment group Biothom and Finnvera Venture Capital. The company, formed in 2006, develops diabetes technologies and services.

Nexstim Oy Raises $15.6M For Medical Devices

Medical device company Nexstim Oy has raised 11.4 million euro ($15.6 million) for its noninvasive brain diagnostic and therapy technologies. New investor Lundbeckfond Ventures led the round, which included participation from new investor Ilmarinen Mutual Pension Insurance Company, and existing investors HealthCap, Life Sciences Partners, Sitra and Finnish Industry Investment Ltd. Founded in 2000, the Finland-based company has raised roughly 30 million euro to date.

Seahorse Raises $5 Million

Seahorse Bioscience, Inc., a Billerica, Mass.-based medical instrument company, closed a $5 million round of financing. Investors in the Series D round included Commonwealth Capital Ventures, FLIR Systems Inc, Rock Maple Ventures, Life Sciences Partners, Oxford Bioscience Partners, Healthcare Ventures, New Science Ventures and HLM Venture Partners.

VC-Backed Movetis Mulls IPO

BRUSSELS (Reuters) – Belgian drugmaker Movetis is considering an initial public offering (IPO) as one of several options to raise capital needed to market its leading product, its chairman said on Friday. A stock market float by the gastrointestinal specialist, which was founded in 2006 as a spin-out from Johnson & Johnson (JNJ.N), could signal […]

PEHUB Community

Join the 12500 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

Psst! Got any hot tips?

  • This field is for validation purposes and should be left unchanged.

PE HUB News Briefs

RSS Feed Widget

Marketplace

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget

Reuters VC and PE feed

RSS Feed Widget